Price Target Update on Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD) : The consensus price target for Amicus Therapeutics (NASDAQ:FOLD) is $14 for the short term with a standard deviation of $3.83. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $19, however, the pessimist price target for the company is $9.

Other Equity analysts have also commented on the company shares. Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $10 per share. The rating by the firm was issued on May 18, 2016.

Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Thursday. Though the stock opened at $5.81, the bulls momentum made the stock top out at $5.93 level for the day. The stock recorded a low of $5.6 and closed the trading day at $5.91, in the green by 2.96%. The total traded volume for the day was 2,417,384. The stock had closed at $5.74 in the previous days trading.

The company shares have dropped -57.98% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $18.83 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $6.63 and the 200 Day Moving Average price is recorded at $7.43. On the companys insider trading activities, Rosenberg Ellen, officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc, executed a transaction worth $115,050 on June 2, 2016. A total of 15,000 shares were purchased at an average price of $7.67. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.